1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Vetnostrum Animal Health Co., Ltd.

Vetnostrum Animal Health Co., Ltd.

TTWSE:6936
32.20
TWD
+0.25
(+0.78%)
1.97EPS
16.60P/E
2.38BMarket Cap
Vetnostrum Animal Health Co., Ltd.
TWSE:6936
(Taiwan Stock Exchange)

Recent

price

32.20

P/E

ratio

16.60

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
- -
19.61
20.14
18.67
18.77
18.23
19.52
20
19.85
Revenue per Share
- -
2.04
1.89
1.74
1.69
1.38
2.06
1.82
1.97
Basic EPS, GAAP
- -
0.29
0.94
1.34
1.67
3.32
2.26
3.72
2.63
Free Cash Flow per Basic Share
- -
1.1
1.48
1.17
1.31
1.21
1.04
1.73
- -
Dividend per Share
12.88
13.68
14
14.6
15.86
16.02
17.04
18.57
18.21
Book Value per Share
12.81
13.63
13.98
14.59
15.85
16.01
17.04
18.57
18.21
Tangible Book Value per Share
66
55
55
63
63
66
66
71
73
Basic Weighted Avg Shares
- -
1,080
1,105
1,176
1,185
1,208
1,294
1,416
1,444
Sales/Revenue/Turnover
- -
12.32
12.2
11.81
10.51
9.23
13.19
11.02
12.26
Operating Margin (%)
- -
46
65
77
78
77
76
74
72
Depreciation Expense
- -
112
104
110
107
92
137
129
144
Net Income, GAAP
- -
22.86
20.8
17.72
18.7
18.96
19.5
19.16
20.28
Effective Tax Rate (%)
- -
10.4
9.38
9.34
8.99
7.59
10.56
9.1
9.94
Profit Margin (%)
261
190
257
309
306
368
469
697
701
Working Capital
78
97
162
151
5
2
14
14
10
LT Debt
853
905
927
967
1,050
1,062
1,130
1,352
1,325
Total Equity
- -
9.32
8.9
9.04
8.05
7.48
11.8
9.81
10.8
Return on Invested Capital (%)
- -
10.53
8.92
9.12
8.76
7.79
11.99
10.21
11.25
Return on Capital (%)
- -
12.78
11.32
11.61
10.56
8.68
12.46
10.38
11.53
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
11
10
11
LT Borrowings
- -
- -
- -
LT Finance Leases
14
12
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
73
73
73
Market Capitalization
2,632
2,497
2,384

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
993
1,060
1,134
Cash, Cash Equivalents & STI
415
459
459
Accounts Receivable, Net
214
227
232
Inventories
323
322
385
Total Current Liabilities
295
302
433
Payables & Accruals
- -
- -
- -
ST Debt
11
10
11
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
8.03%
19.62%
Free Cash Flow
- -
48.07%
75.3%
Net Income, GAAP
- -
6.48%
-5.68%
Sales/Revenue/Turnover
- -
5.14%
9.43%
Total Cash Common Dividend
- -
12.73%
78.01%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
280
328
361
326
1,294
2025
341
328
- -
373
1,416
2026
368
376
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.41
0.47
0.63
0.54
2.06
2025
0.53
0.21
- -
0.62
1.82
2026
0.6
0.54
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.04
2025
- -
- -
- -
- -
1.73
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Vetnostrum Animal Health Co., Ltd. (6936.TWO) manufactures and sells animal health products, including veterinary pharmaceuticals, medicated feed additives, non-medicated feed additives, and pet-use drugs and supplements; it offers therapeutic drugs for respiratory, gastrointestinal, and reproductive issues in livestock such as swine, ruminants, poultry, and aquatics, alongside customized vitamin and mineral premixes, probiotics like Prostrum and Enzapro, green feed additives such as YungClean, and companion animal products under the Koolpal brand for skin care, eye health, cardiovascular support, and deworming. Founded in 2012 and headquartered in Hsinchu, Taiwan, as a member of Yung Shin Pharmaceutical Industrial Co., Ltd. (3705.TW), the company holds over 350 product licenses and permits across Taiwan, Japan, China, Southeast Asia, and Latin America, serving feed mills, livestock farms, distributors, veterinary clinics, and end-users through online and offline channels; it maintains 15 production lines with WHO GMP, FAMI-QS, and ISO 9001 certifications, including sterile injectable facilities meeting human pharmaceutical standards, and provides technical services via veterinarian and consultant teams. Vetnostrum operates primarily in Taiwan and the Asia-Pacific region, partnering with global firms like Novus International (under Mitsui & Co.), Great Wall Enterprise, Charoen Pokphand Enterprise, and Taiwan Sugar Corporation's Livestock Division. Recent developments include its April 2025 listing on the Taipei Exchange (TPEX), WHO GMP certification acceptance by Malaysia's NPRA in May 2024 enabling expanded market access, approval of the green feed additive YungClean in Malaysia and the Philippines in February 2024, launch of the probiotic Prostrum in Indonesia in August 2023, and new veterinary product introductions for livestock and companion animals in April 2023, alongside ongoing participation in international expos like VIV Asia 2025 and facility expansions to support growth.